



To promote excellence in clinical diagnosis, research, technical development, and education in cardiovascular imaging in Europe.

Elections to EACVI Board and Sections 2016-2018

Application for the position:

Councilor



1. Your Identity

Title: PhD

Family Name(s): Magne

First Name(s): Julien

Birth Date: 26/01/1980

Type of address: Business

Institute/Organisation: CHU Limoges

Department: Cardiology

Address: 2, Avenue Martin Luther King

Post Code/Zip: 87 042

City: Limoges

Country: France





To promote excellence in clinical diagnosis, research, technical development, and education in cardiovascular imaging in Europe.

Elections to EACVI Board and Sections 2016-2018

2. General Curriculum Vitae (300 words max)

Education and Qualification

September 2008 - September 2010: Postdoctoral fellowship, University of Liège, Belgium.

May 2004 - August 2008: PhD training program, Experimental Medicine, Laval University, Quebec City, Canada.

2002/2003: Master training, Exercise Physiology, University Toulouse III, France.

Work Experiences

January 2014 - till now: Researcher Associated, CHU Dupuytren, Cardiology Department Limoges, France.

October 2010- December 2013: Research Associate F.R.S-FNRS, CHU Sart Tilman, Cardiology Department. University of Liège, Liège, Belgium.

September 2008 - September 2010: Postdoctoral fellowship, CHU Sart Tilman. University of Liège, Liège, Belgium.

May 2004 - July 2008: PhD training, Research Center of Laval Hospital, Laval University.

From 2000 to 2003: Master training, Clinic of Rehabilitation, Saint-Orens, France.

Supervisory experience since 2008

PhD training: Co-supervisor of 3 students **Fellow research training:** 7 students

Cardiology program training: end-study thesis, 12 students

Master program training: 4 students

Publications

 \approx 100 peer reviewed articles (\approx 65 original articles, \approx 20 letters, invited editorials or position papers)

Abstract presentations in international meetings >30 orals; >60 posters

Invited conferences in international meetings ESC/AHA/ACC/Euroecho/ASE/Heart Failure/EACVI teaching courses/World Summit of Echocardiography

Position in Scientific Organisations

EACVI Councilor: 2014-2016

Scientific programme director: **Euroecho** congress (2010-16) Research and Innovation Committee, **EACVI**, member (2012-16)

Membership in scientific organizations

- ✓ Associate member, Scientific Council of the French Society of Vascular Disease (since 2012).
- ✓ Member, European Association of Cardiovascular Imaging (since 2009).
- ✓ Member, Working Group of Valvular Heart Disease, European Society of Cardiology (since 2010).

Research interests

Cardiac Imaging, Echocardiography, Stress Echocardiography, Valvular Heart Disease, LV Function, Pulmonary Vascular Function, Pulmonary Hypertension, Vascular disease, Statistics, Methodology, Trial Design.





To promote excellence in clinical diagnosis, research, technical development, and education in cardiovascular imaging in Europe.

Elections to EACVI Board and Sections 2016-2018

3. Previous experience(s) in the EACVI or ESC or your National Bodies?

EACVI and ESC

Member of the EACVI since 2009 Board member of the EACVI since 2014

Elected councilor of the EACVI since 2014

Member of the Working Group on Valvular Heart Diseases, European Society of Cardiology (since 2010)

Co-director, director and advisor of the Scientific programme of **Euroecho Imaging**: Budapest 2011, Athens 2012, Istanbul 2013, Vienna 2014, Seville 2015 and Leipzig 2016

Active member of the Research and Innovation Committee, **EACVI** (2012-14 and 2014-16)

Active participation to the Valvular Box of the EACVI.

National society

Associate member, Scientific Council of the French Society of Vascular Disease (since 2012)

4. Are you a Board or Nucleus Member of another scientific organisation?

If Yes, please specify

No





To promote excellence in clinical diagnosis, research, technical development, and education in cardiovascular imaging in Europe.

Elections to EACVI Board and Sections 2016-2018

Publications (please list 10 max)

- **1- Magne J**, Mathieu P, Dumesnil J.G, Tanné D, Dagenais F, Doyle D, Pibarot P. Impact of Prosthesis-Patient Mismatch on Survival After Mitral Valve Replacement. **Circulation**, 2007;115:1417-1425.
- **2- Magne J**, Pibarot P, Dagenais F, Hachicha Z, Dumesnil J.G, Sénéchal M. Preoperative Posterior Leaflet Angle Accurately Predicts Outcome after Restrictive Mitral Valve Annuloplasty for Ischemic Mitral Regurgitation. **Circulation**, 2007;115:782-791.
- **3- Magne J**, Sénéchal M, Mathieu P, Dumesnil J.G, Dagenais F, Pibarot P. Restrictive Annuloplasty for Ischemic Mitral Regurgitation May Induce Functional Mitral Stenosis. **Journal of the American College of Cardiology**, 2008 Apr 29;51(17):1692-701.
- **4- Magne J**, Sénéchal M, Mathieu P, Dumesnil J.G, Dagenais F, Pibarot P. Restrictive Annuloplasty for Ischemic Mitral Regurgitation May Induce Functional Mitral Stenosis. **Journal of the American College of Cardiology**, 2008 Apr 29;51(17):1692-701.
- **5- Magne J**, Girerd N, Sénéchal M, Mathieu P, Dagenais F, Dumesnil JG, Charbonneau E, Voisine P, Pibarot P. Mitral Repair Versus Replacement for Ischemic Mitral Regurgitation: Comparison of Short- and Long- Term Survival. **Circulation**, 2009 Sep 15;120(11 Suppl):S104-11.
- **6- Magne J**, Lancellotti P, Piérard L. Exercise-induced Changes in Degenerative Mitral Regurgitation. **Journal of the American College of Cardiology**, 2010, 56:300–9.
- **7- Magne J**, Lancellotti P, Piérard LA. Exercise Pulmonary Hypertension in Asymptomatic Degenerative Mitral Regurgitation. **Circulation**, 2010 122(1):33-41.
- **8- Magne J**, Mahjoub H, Pierard LA, Dulgheru R, Pibarot P, Lancellotti P. Left Ventricular Contractile Reserve in Asymptomatic Primary Mitral Regurgitation. **European Heart Journal**, 2014 Jun 21;35(24):1608-16.
- **9- Magne J**, Pibarot P, Sengupta PP, Donal E, Rosenhek R, Lancellotti P. Pulmonary hypertension in valvular disease: a comprehensive review on pathophysiology to therapy from the HAVEC Group. **JACC Cardiovasc Imaging**. 2015 Jan;8(1):83-99.
- **10- Magne J**, Szymanski C, Fournier A, Malaquin D, Avierinos JF, Tribouilloy C. Clinical and Prognostic Impact of a New Left Ventricular Ejection Index in Primary Mitral Regurgitation Because of Mitral Valve Prolapse. **Circ Cardiovasc Imaging**. 2015 Sep;8(9):e003036.






To promote excellence in clinical diagnosis, research, technical development, and education in cardiovascular imaging in Europe.

6. Received Hirsch Index: Year / Index

From 2007, H=24







To promote excellence in clinical diagnosis, research, technical development, and education in cardiovascular imaging in Europe.

7. Received Impact Factor(s): Year / IF

Year	Impact factor	Year	Impact factor
2007	28	2012	62
2008	35	2013	64
2009	40	2014	100
2010	40	2015	84
2011	23	2016	73

Average: 65 / year

8. Why are you interested in joining the EACVI Board (150 words max)?

The **EACVI** is one of the most active Associations of the ESC, it provides continuing research and education in order to further improve knowledge and skills in the field of cardiac imaging. Being part of this 'team' and working with the other experts and key opinion leaders in cardiac imaging has been a great honor and pleasure during these last 2 years.

I apply as **councilor** for the 2 next years in order to extend my previous work with the Board of the EACVI and the research and innovation committee.

My main goals as councilor will be to help to (1) increase **membership**, more particularly among the **young** community, (2) foster **scientific** discussion, (3) promote and develop **education** program and **teaching** courses, (4) improve the **research** and scientific activities, (5) promote good **clinical practice** in the field, and, (6) contribute to improve the relationship between the Association and **national societies**.